MUMBAI, India, Jan. 23 -- Intellectual Property India has published a patent application (202511124959 A) filed by GLA University, Mathura, Uttar Pradesh, on Dec. 11, 2025, for 'targeted nanoparticle system for inflammatory and autoimmune drug delivery.'
Inventor(s) include Rajat Yadav; and Arockia Babu.
The application for the patent was published on Jan. 23, under issue no. 04/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a targeted nanoparticle system for delivery of an active drug to inflammatory and autoimmune sites. A nanoparticle core module retains the drug while a targeting-ligand interface is interleaved with a stability and circulation module that forms a hydrated steric layer to suppress protein adsorption and opsonization without masking ligands. A stimuli-responsive release module is configured to bias release under mildly acidic conditions relative to physiological pH, thereby concentrating payload at diseased tissue while moderating loss in circulation. Representative implementations yield nanoparticles with controlled hydrodynamic diameter and narrow size distribution, defined composition bands for core, drug, ligands, and stabilizers, and loading efficiency suitable for parenteral use. The coordinated architecture establishes a predictable pharmacokinetic window and supports selective therapy."
Disclaimer: Curated by HT Syndication.
